# Semaglutide: Research Overview — aminopeptides.net > A literature summary of semaglutide: GLP-1 receptor mechanism, the STEP and SELECT trial findings, kidney and cardiovascular outcomes, FDA approval status, and documented safety considerations. A long-acting GLP-1 receptor agonist with FDA approval across multiple metabolic indications — what the large randomized trials actually found, and what the safety literature documents. ## The short version Semaglutide is a **31-amino-acid peptide** that mimics a natural gut hormone called GLP-1 (glucagon-like peptide-1). Your body releases GLP-1 after a meal; it tells the pancreas to release insulin, tells the stomach to slow down, and signals the brain that you have eaten. Semaglutide does the same things, but it resists breakdown and circulates for roughly a week rather than the ~2 minutes of the natural hormone. It is FDA-approved — for type 2 diabetes management, for weight management in people with obesity or overweight plus a weight-related condition, for reducing cardiovascular events in people with established cardiovascular disease and overweight, and since 2025 for metabolic-related liver disease (MASH). The largest trials enrolled tens of thousands of participants and produced some of the most significant metabolic-disease results of the 2020s [2][3][4]. This page summarizes that research. It does not recommend semaglutide, discuss prescribing, or list doses. It covers what the clinical trials found, what safety signals the literature documents, and what real-world users report — clearly labeled as anecdotal. ## What it is Semaglutide is a *long-acting acylated analogue* of human GLP-1, sharing approximately 94% sequence homology with the native hormone. Two backbone substitutions give it protease resistance: at position 8, an alanine is replaced by alpha-aminoisobutyric acid (Aib), which blocks the enzyme DPP-4 from cleaving the peptide; at position 34, lysine is replaced by arginine. A single fatty di-acid side chain is attached at position 26 via a glutamic-acid/ADO spacer. That lipid tether binds reversibly to serum albumin in the bloodstream, which shields the peptide from renal clearance and accounts for the roughly one-week half-life that enables once-weekly dosing. Semaglutide is available as a once-weekly subcutaneous injection and a once-daily oral tablet (the oral form uses the absorption enhancer SNAC to achieve ~0.4–1% oral bioavailability). It is a regulated prescription medicine when dispensed as the manufactured product. The generic compound name is semaglutide; brand names are excluded from this desk per its trademark policy. ## How it works Semaglutide activates the **GLP-1 receptor (GLP-1R)**, a G-protein-coupled receptor expressed throughout the body. Its weight-lowering and glucose-lowering effects come from several converging pathways: - *Pancreatic beta cells*: GLP-1R activation potentiates glucose-dependent insulin secretion — it boosts insulin only when blood glucose is elevated, which reduces hypoglycemia risk. - *Pancreatic alpha cells*: It suppresses inappropriate glucagon release. - *Gastric smooth muscle and vagal afferents*: Slows gastric emptying, flattening postprandial glucose spikes and extending feelings of fullness. - *Hypothalamus and brainstem*: Semaglutide crosses the blood-brain barrier and reaches appetite circuits in the arcuate nucleus and area postrema. There it activates anorexigenic POMC/CART neurons and inhibits orexigenic NPY/AgRP neurons, reducing food intake and modifying food preference. This central appetite suppression — often described by users as "quieter food noise" — is the primary driver of its weight-loss effect. - *Cardiovascular and renal GLP-1Rs*: Pleiotropic protective effects on heart and kidney, substantiated by the SELECT and FLOW trials. ## What the research shows **Weight management (STEP 1, 2021).** In a 68-week randomized trial of 1,961 adults with overweight or obesity but no diabetes, once-weekly subcutaneous semaglutide 2.4 mg produced a mean body-weight change of **−14.9%** versus −2.4% with placebo — a treatment difference of approximately 12.4 percentage points [4]. **Head-to-head weight comparison (SURMOUNT-5, 2025).** In a 72-week head-to-head trial of 751 adults with obesity, tirzepatide (a dual GIP/GLP-1 agonist) produced greater weight loss than semaglutide (−20.2% vs −13.7%; P<0.001) [1]. This is the most rigorous direct-comparison data available as of 2025. **Cardiovascular outcomes (SELECT, 2023).** In 17,604 adults with preexisting cardiovascular disease and overweight or obesity but *without* diabetes, once-weekly semaglutide 2.4 mg reduced the primary composite of CV death, nonfatal myocardial infarction, or nonfatal stroke versus placebo (HR 0.80; 95% CI 0.72–0.90; P<0.001) — a 20% relative risk reduction [3]. This trial established cardiovascular benefit independent of diabetes status. **Kidney outcomes (FLOW, 2024).** In 3,533 people with type 2 diabetes and chronic kidney disease, semaglutide 1.0 mg reduced the primary kidney composite (kidney failure, ≥50% eGFR decline, or kidney or cardiovascular death) versus placebo (HR 0.76; 95% CI 0.66–0.88) — a 24% lower risk [2]. **Safety profile overview (2021 review).** A dedicated safety analysis concluded that semaglutide has a favorable overall benefit-risk profile with gastrointestinal effects as the dominant adverse-event class (nausea in roughly one-third of patients), a confirmed increase in biliary disease (cholelithiasis), and pancreatic and thyroid-cancer signals for which definitive conclusions cannot yet be drawn due to low incidence [5]. ## Reported effects, cautions & safety The following signals come from community-review aggregators and patient-experience sources. They are **anecdotal, not clinical evidence**. They describe what people report, not what clinical trials have established. **Frequently reported benefits.** - *Appetite suppression and quieter "food noise"*: By far the most commonly described benefit — a reduction in the constant background preoccupation with food, often within the first week or two. People describe feeling full faster and eating much smaller portions. - *Reduced cravings*: Sweet, sugary, and greasy food cravings drop sharply or disappear for many users, with food preferences often shifting toward lighter options. - *Weight loss*: The overwhelming majority of reviewers report losing weight, describing it as steady and substantial over months. - *Improved blood-sugar control* (among people with type 2 diabetes): Markedly improved fasting glucose and A1C readings. - *Reduced desire to drink alcohol*: A recurring secondary observation across patient communities — the urge to drink fades alongside food cravings. **Frequently reported adverse effects.** - *Nausea (sometimes with vomiting)*: The single most-reported side effect, mentioned by roughly a third of reviewers, typically peaking in the first weeks and after each dose increase. Worse after overeating or fatty food. - *Sulfur or "egg" burps*: A distinctive complaint — foul-smelling burps appearing after dose increases, sometimes lasting hours or weeks, often accompanied by bloating. - *Constipation and/or diarrhea*: Both are reported, sometimes alternating, reflecting gastric-emptying effects. - *Fatigue early on*: Tiredness in the first day or two after each injection, usually easing with time. - *Hair shedding*: Increased shedding noted by some users a few months in, widely attributed to rapid weight loss (telogen effluvium) rather than the medication directly — consistent with pharmacovigilance signals in the literature. **Cautions documented in clinical literature.** - *Gastrointestinal intolerance during dose escalation*: The dominant adverse-effect class in trials; the leading cause of discontinuation [5]. - *Personal or family history of medullary thyroid carcinoma or MEN-2*: A boxed warning based on rodent findings; the human thyroid-cancer signal is unconfirmed but the contraindication stands [5]. - *Acute pancreatitis*: A class warning for GLP-1 receptor agonists; treatment is discontinued if pancreatitis is suspected [5]. - *Gallbladder disease (cholelithiasis)*: A confirmed increase versus placebo, attributed largely to the rate and magnitude of weight loss [5]. - *Diabetic retinopathy with rapid glycemic correction*: In SUSTAIN-6, rates of retinopathy complications were significantly higher with semaglutide (HR 1.76) among patients with pre-existing retinopathy undergoing rapid HbA1c lowering; monitoring is advised. - *Lean mass loss*: Body-composition substudies show a meaningful proportion of weight lost is lean mass, raising sarcopenia concerns especially in older adults. - *Weight regain after discontinuation*: Controlled trial extensions show substantial weight regain after stopping semaglutide, framing it as a chronic rather than curative treatment. - *Pregnancy*: Contraindicated; the approximately one-week half-life means a washout period is advised before planned conception. - *Oral formulation requires strict fasted administration*: The SNAC-enabled formulation has very low oral bioavailability (~0.4–1%); administration errors reduce efficacy substantially. ## Where semaglutide fits in this desk Semaglutide is the most clinically validated compound on this desk by a significant margin. Its regulatory approval across multiple indications, its Phase 3 trial record spanning tens of thousands of participants, and its cardiovascular-outcome data set it apart from both MOTS-c (research-chemical, no human trials) and NAD+ (dietary-supplement framing, precursor-dependent bioavailability, limited clinical endpoint data). It belongs here because it is also, structurally, a peptide — an engineered analogue of a natural peptide hormone — and because the metabolic pathways it engages (GLP-1R signaling, insulin sensitivity, cardiovascular risk) overlap meaningfully with the aging-biology questions that motivate research into MOTS-c and NAD+. See the [comparison page](/compare) for how all three sit relative to each other. --- An independent reading desk for the published biology of metabolic aging — citations, not prescriptions.